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This issue of Clinical Microbiology and Infection includes two
articles that have been sponsored by the European Society
of Clinical Microbiology and Infectious Diseases (ESCMID)
and are the result of the work of a committee of experts
under the leadership of E Kuijper. They concern diagnosis
and management of Clostridium difﬁcile infection (CDI) and
C. difﬁcile-associated disease (CDAD).
Disease caused by this organism occurs only in individuals
who are infected with toxin-producing strains of C. difﬁcile and
ranges from mild diarrhoea to severe enterocolitis that can be
associated with toxic megacolon, colon perforation and multi-
organ failure. It is the commonest healthcare-associated gas-
tro-intestinal infection and usually follows antibiotic use.
In Europe, until very recently, the problem of CDI was
increasing rapidly. In a study of 2856 Clostridium patients
from 34 hospitals in Germany conducted over 12 months
between 2007 and 2008, the incidence was 46.5 per 10 000
admitted patients, but varied widely among hospitals. Sev-
enty-three per cent of cases were hospital-acquired and
8.4% were classiﬁed as severe. The differences among the
hospitals correlated with local diagnostic and infection con-
trol procedures [1]. Likewise, until recently, mortality attrib-
utable to CDI has been steadily rising; for example, in
Finland the age-standardized mortality rate associated with
CDI increased from 9 per million in 1998 to 17 per million
in 2004. This increase was seen only in individuals 65 years
of age or older [2].
However, there is some new evidence suggesting that in a
number of regions the problem is starting to respond to
enhanced infection control policies and case management.
While the number of death certiﬁcates in England and Wales
mentioning C. difﬁcile infection increased annually between
1999 and 2007, in 2008 this ﬁgure fell by 29%, from 8324 to
5931. Among death certiﬁcates citing C. difﬁcile, those attrib-
uting death to the organism decreased slightly from a previ-
ous level of 55% to 49% in 2007. This percentage decreased
further in 2008 to 42% (Ofﬁce for National Statistics 19
August 2009. http://www.statistics.gov.uk/cci/nugget.asp?id=
1735).
Microbiological epidemiology reveals wide and dynamic
variations in strain prevalence. In a study of almost 900
strains from 16 countries worldwide, REA group BI (Ribo-
type 027) isolates were the most common strains identiﬁed
and were widely distributed throughout North America, but
restricted to three of 13 countries in Europe, where REA
group J (Ribotype 001) isolates were the most frequent [3].
However, within Europe, there is also wide variation among
regions and a constantly changing epidemiology. In England
and Wales, between 2007 and 2008, Ribotype 027 was the
commonest strain isolated from symptomatic patients (41.3%
of over 600 isolates), followed by Type 106 (20.2%) while
Type 001, once the most common strain associated with
hospital outbreaks, accounted for only 7.8% [4].
In hospital practice a wide array of diagnostic tests is avail-
able for microbiology laboratories but they vary greatly in
sensitivity and speciﬁcity. The tests available include enzyme-
linked immunosorbent assay for toxins A and B, tissue cul-
ture cytotoxicity for toxin B, and direct culture of the organ-
ism. In an ESCMID-sponsored systematic review published in
this issue, Crobach and colleagues evaluate the available evi-
dence on laboratory diagnosis of CDI and formulate recom-
mendations to optimize CDI testing in patients suspected of
CDI. Their work is a valuable resource for microbiology pro-
fessionals and policy makers, and is probably the best avail-
able systematic review of the performance of the many tests
available for diagnosis of CDI.
For many years, the mainstays of drug treatment of
CDAD have been metronidazole and vancomycin. Oral met-
ronidazole remains standard therapy in most countries of
Europe, especially for mild disease, but there is recent evi-
dence of loss of effectiveness in treating CDAD [5]. The
European Society of Clinical Microbiology and Infectious Dis-
eases (ESCMID) Guidance Document for Clostridium difﬁcile
infection (CDI) diagnosis and treatment published in this
issue, put together by MP Bauer and colleagues, is a powerful
new resource. This document, produced after wide consulta-
tion, provides guidance for European practitioners on the
use of antibiotics, optimal doses and durations of therapy,
use of susceptibility testing, management of severe infections,
and the place of surgery.
A particular problem for practising clinicians is manage-
ment of recurrent CDI, and Bauer and colleagues provide
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general recommendations for dealing with this. Repeated and
prolonged therapy is often necessary and sometimes unsuc-
cessful. Other potentially effective strategies include use of
vancomycin with adjunctive treatments, such as Saccharomy-
ces boulardii, rifaximin ‘chaser’ therapy after vancomycin,
newer agents such as nitazoxanide, faecal transplantation,
and intravenous immunoglobulin [6].
Since 2006, the European Centre for Disease Prevention
and Control (ECDC) has approached the problem of control-
ling CDI by fostering the coordination of national surveillance
activities across Europe, encouraging the standardization of
typing and microbiological diagnosis, and developing best
practice guidance to member states [7]. Efforts continue to
enhance surveillance and encourage best practice in Europe,
and these two ESCMID-sponsored documents will help
greatly to improve control of this distressing disease.
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